Innovation Drives The Discovery For Novel Medicine
Committed to the Discovery of Cutting-Edge
Immuno-oncology Therapeutics
Finding Solutions to Cancer Immune Escape by Targeting TMER
Crossignal Therapeutics is developing a new generation of small molecule anti-cancer immunotherapies. We focus on the discovery of immune cell-expressed, tumor metabolic factors (TME)-targeted GPCRs (TMERs) as drug targets and design our drug candidates by testing their ability to inhibit critical pathways in TME-mediated cancer immune escape.
Current Pipeline Programs
CT3001
Clinical stage Ph1 “First-in-Class” small molecule inhibitor of GPR35, discovered by Crossignal with full IP and world-wide commercial rights.
CT3021
Potential “Best-in-Class” small molecule inhibitor of adenosine receptors, discovered by Crossignal with full IP and world-wide commercial.
A novel assay platform (PPS)
Enable drug screening toward difficult and previously undruggable GPCR targets.
Early-stage discovery programs at various stages of pre-clinical development, a rich pipeline with potential to grow.